Clinical effect and safety profile of recombinant human lysosomal acid lipase in patients With cholesteryl ester storage disease

Hepatology

Volumn 58, Issue 3, 2013, Pages 950-957

  Balwani, Manisha ^a   Breen, Catherine ^b   Enns, Gregory M ^c   Deegan, Patrick B ^d   Honzík, Tomas ^e   Jones, Simon ^b   Kane, John P ^f   Malinova, Vera ^e   Sharma, Reena ^g   Stock, Eveline O ^f   Valayannopoulos, Vassili ^h   Wraith, J Edmond ^b   Burg, Jennifer ⁱ   Eckert, Stephen ⁱ   Schneider, Eugene ⁱ   Quinn, Anthony G ⁱ  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b ST MARY S HOSPITAL   (United Kingdom)

^c STANFORD UNIVERSITY   (United States)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

^e CHARLES UNIVERSITY   (Czech Republic)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g HOPE HOSPITAL   (United Kingdom)

^h HÔPITAL NECKER ENFANTS MALADES   (France)

ⁱ Synageva BioPharma Corp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SEBELIPASE ALFA; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL ESTER STORAGE DISEASE; CLINICAL TRIAL; DIARRHEA; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; CHOLESTEROL ESTER STORAGE DISEASE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LIVER; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; STEROL ESTERASE; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84883460510     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26289     Document Type: Article

References (29)

1. Grabowski G, Charnas L, Du H. Acid lipase deficiency: Wolman disease and cholesteryl ester storage disease. In: Beaudet A, Vogelstein B, Kinzler K, Antonarakis S, Ballabio A, eds.The Metabolic and Molecular Basis of Inherited Metabolic Disease (Online). 8th ed.New York:McGraw-Hill;2012.
2. Beaudet AL, Ferry GD, Nichols BL Jr, Rosenberg HS.Cholesterol ester storage disease: clinical, biochemical, and pathological studies.J Pediatr 1977;90:910-914.
3. Elleder M, Chlumska A, Ledvinova J, Poupetova H.Testis - a novel storage site in human cholesteryl ester storage disease. Autopsy report of an adult case with a long-standing subclinical course complicated by accelerated atherosclerosis and liver carcinoma.Virchows Arch 2000;436:82-87.
4. Ginsberg HN, Le NA, Short MP, Ramakrishnan R, Desnick RJ.Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis.J Clin Invest 1987;80:1692-1697.
5. Di Bisceglie AM, Ishak KG, Rabin L, Hoeg JM.Cholesteryl ester storage disease: hepatopathology and effects of therapy with lovastatin.Hepatology 1990;11:764-772.
6. Tarantino MD, McNamara DJ, Granstrom P, Ellefson RD, Unger EC, Udall JN Jr.Lovastatin therapy for cholesterol ester storage disease in two sisters.J Pediatr 1991;118:131-135.
7. Yokoyama S, McCoy E.Long-term treatment of a homozygous cholesteryl ester storage disease with combined cholestyramine and lovastatin.J Inherit Metab Dis 1992;15:291-292.
8. Glueck CJ, Lichtenstein P, Tracy T, Speirs J.Safety and efficacy of treatment of pediatric cholesteryl ester storage disease with lovastatin.Pediatr Res 1992;32:559-565.
9. Gasche C, Aslanidis C, Kain R, Exner M, Helbich T, Dejaco C, et al.A novel variant of lysosomal acid lipase in cholesteryl ester storage disease associated with mild phenotype and improvement on lovastatin.J Hepatol 1997;27:744-750.
10. Tadiboyina VT, Liu DM, Miskie BA, Wang J, Hegele RA.Treatment of dyslipidemia with lovastatin and ezetimibe in an adolescent with cholesterol ester storage disease.Lipids Health Dis 2005;4:26.
11. Hansen K, Horslen S.Metabolic liver disease in children.Liver Transpl 2008;14:713-733.
12. Besley GT, Broadhead DM, Lawlor E, McCann SR, Dempsey JD, Drury MI, et al.Cholesterol ester storage disease in an adult presenting with sea-blue histiocytosis.Clin Genet 1984;26:195-203.
13. Meyers WF, Hoeg JH, Demosky BS, Herbst JJ, Brewer HB.The use of parenteral hyperalimentation and elemental formula feeding in the treatment of Wolman disease.Nutr Res 1985;5:423-429.
14. Du H, Levine M, Ganesa C, Witte DP, Cole ES, Grabowski GA.The role of mannosylated enzyme and the mannose receptor in enzyme replacement therapy.Am J Hum Genet 2005;77:1061-1074.
15. Du H, Cameron TL, Garger SJ, Pogue GP, Hamm LA, White E, et al.Wolman disease/cholesteryl ester storage disease: efficacy of plant-produced human lysosomal acid lipase in mice.J Lipid Res 2008;49:1646-1657.
16. Anderson RA, Sando GN.Cloning and expression of cDNA encoding human lysosomal acid lipase/cholesteryl ester hydrolase. Similarities to gastric and lingual lipases.J Biol Chem 1991;266:22479-22484.
17. Quinn AG, Harvey A, Chen M, Christmann L, Leavitt M, Hu W, et al.SBC-102, a recombinant enzyme replacement therapy, corrects key abnormalities due to lysosomal acid lipase deficiency.Washington, DC:American Society of Human Genetics (ASHG);2010.
18. Yoshida H, Kuriyama M.Genetic lipid storage disease with lysosomal acid lipase deficiency in rats.Lab Anim Sci 1990;40:486-489.
19. Kuriwaki K, Yoshida H.Morphological characteristics of lipid accumulation in liver-constituting cells of acid lipase deficiency rats (Wolman's disease model rats).Pathol Int 1999;49:291-297.
20. Leavitt M, Burt AD, Hu W, Canty D, Gray M, Bray A, et al.Recombinant lysosomal acid lipase normalized liver weight, transaminases and histopathological abnormalities in an in vivo model of cholesterol storage ester disease.J Hepatol 2011;54( Suppl 1):S358.
21. Leavitt M, Hu W, Canty D, Gray M, Bray A, Rutkowski J, et al.Efficacy of SBC-102, a recombinant enzyme replacement therapy, across a broad range of doses in an in vivo model of lysosomal acid lipase deficiency.J Pediatr Gastroenterol Nutr 2011;52( Suppl 1):E20.
22. Evstatiev R, Gasche C.Iron sensing and signalling.Gut 2012;61:933-952.
23. Al Essa M, Nounou R, Sakati N, Le Quesne G, Joshi S, Archibald A, et al.Wolman's disease: the King Faisal Specialist Hospital and Research Centre experience.Ann Saudi Med 1998;18:120-124.
24. Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M, et al.Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products.J Immunol Methods 2004;289:1-16.
25. Shankar G, Devanarayan V, Amaravadi L, Barrett YC, Bowsher R, Finco-Kent D, et al.Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products.J Pharm Biomed Anal 2008;48:1267-1281.
26. Vitner EB, Platt FM, Futerman AH.Common and uncommon pathogenic cascades in lysosomal storage diseases.J Biol Chem 2010;285:20423-20427.
27. vom Dahl S, Harzer K, Rolfs A, Albrecht B, Niederau C, Vogt C.S et al.Hepatosplenomegalic lipidosis: what unless Gaucher? Adult cholesteryl ester storage disease (CESD) with anemia, mesenteric lipodystrophy, increased plasma chitotriosidase activity and a homozygous lysosomal acid lipase -1 exon 8 splice junction mutation.J Hepatol 1999;31:741-746.
28. Holmes RS, Cox LA, VandeBerg JL.Comparative studies of mammalian acid lipases: evidence for a new gene family in mouse and rat (Lipo).Comp Biochem Physiol Part D Genomics Proteomics 2010;5:217-226.
29. Bowden KL, Bilbey NJ, Bilawchuk LM, Boadu E, Sidhu R, Ory DS, et al.Lysosomal acid lipase deficiency impairs regulation of ABCA1 gene and formation of high density lipoproteins in cholesteryl ester storage disease.J Biol Chem 2011;286:30624-30635.